Setmelanotide in Bardet-Biedl Syndrome: A Case Report.

This case report describes a patient with Bardet-Biedl Syndrome who was treated with a medication called setmelanotide. Setmelanotide is a drug that helps control extreme hunger (called hyperphagia) that often occurs in people with Bardet-Biedl Syndrome and can lead to severe weight gain. The medication works by targeting specific receptors in the brain that help regulate appetite. The main finding was that the patient developed skin darkening (hyperpigmentation) all over their body, which is the most common side effect of this medication. The researchers reviewed other studies and found that setmelanotide can also cause changes to moles and other skin spots. Because of these skin-related side effects, they recommend that patients taking setmelanotide should have their skin examined by a dermatologist before starting treatment and then once a year while taking the medication. This is important for families to know because while setmelanotide can be helpful for controlling the excessive hunger that's common in Bardet-Biedl Syndrome, patients need regular skin monitoring to watch for any concerning changes. The exact guidelines for how often to check the skin are still being developed, but yearly dermatology visits appear to be a good precaution for anyone taking this medication.

Setmelanotide is a melanocortin-4-receptor agonist used for the treatment of hyperphagia in the genetic obesity syndrome Bardet-Biedl. Presented is a case of diffuse hyperpigmentation in a patient treated with setmelanotide, which represents the most common side effect of this medication. Herein is a review of the literature for other potential side effects that warrant regular dermatologic screening, including alteration of existing melanocytic lesions. Exact screening guidelines have not been completely defined, though it is recommended that patients receive baseline and annual examinations while undergoing treatment with this agent.